Casperome® is a formulation comprising an extract of Boswellia serrata, a tree belonging to the Burseraceae family that grows in India, the Middle East and North Africa and whose biologically active constituents, 3-acetyl-11-keto-β-boswellic acid and β-boswellic acid, are credited with anti-inflammatory and anti-arthritic activity.

The composition includes soya lecithin in an equal ratio and, to improve the physical stability of the product, microcrystalline cellulose.

Absorption of Casperome® is rapid and tissue and plasma levels have been shown to be higher than with other boswellic acids (1).

Casperome® also improved symptoms in healthy subjects with mild irritable bowel syndrome (2) and in the management of ulcerative colitis in remission (3).

The most relevant studies on this ingredient have been selected with a summary of their contents:

Casperome® studies

References________________________________________________________________________

(1) Loeser K, Seemann S, König S, Lenhardt I, Abdel-Tawab M, Koeberle A, Werz O, Lupp A. Protective Effect of Casperome®, an Orally Bioavailable Frankincense Extract, on Lipopolysaccharide- Induced Systemic Inflammation in Mice. Front Pharmacol. 2018 Apr 20;9:387. doi: 10.3389/fphar.2018.00387.

(2) Riva A, Giacomelli L, Togni S, Franceschi F, Eggenhoffner R, Zuccarini MC, Belcaro G. Oral administration of a lecithin-based delivery form of boswellic acids (Casperome®) for the prevention of symptoms of irritable bowel syndrome: a randomized clinical study. Minerva Gastroenterol Dietol. 2019 Mar;65(1):30-35. doi: 10.23736/S1121-421X.18.02530-8. 

(3) Pellegrini L, Milano E, Franceschi F, Belcaro G, Gizzi G, Feragalli B, Dugall M, Luzzi R, Togni S, Eggenhoffner R, Giacomelli L. Managing ulcerative colitis in remission phase: usefulness of Casperome®, an innovative lecithin-based delivery system of Boswellia serrata extract. Eur Rev Med Pharmacol Sci. 2016 Jun;20(12):2695-700.